COMPANY

Nanochon, Inc.

Also known as Nanochon · 3 sources

Keywords: musculoskeletal Knee Cartilage Lesions Nanochon Chondrograft

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Seed · $4.1M · announced Jan 12, 2026 Company release ↗
Source quote
- Jan 12, 2026 · Company release ↗
  “Nanochon closes $4.1M Seed Prime II Funding Round”

Raises announced in these releases: $4.1M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Jul 30, 2026 Trial start Not phased (device or behavioral study): Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Panama source ↗
Jan 12, 2026 Raise Private equity round: $4.1M (total, as published), announced Jan 12, 2026. Source: company's own press page. source ↗ · Form D filed Feb 5, 2026 SEC Form D ↗
Jan 12, 2026 Raise Seed · $4.1M source ↗
2026-10 Trial start Not phased (device or behavioral study): Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada source ↗

2027-09 (ESTIMATED) · Not phased · Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Panama · NCT07542184
2028-01 (ESTIMATED) · Not phased · Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada · NCT07249489

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $4.1M. Last 2 years.

Jan 12, 2026 Private equity round: $4.1M (total, as published), announced Jan 12, 2026. Source: company's own press page. source ↗ · Form D filed Feb 5, 2026 SEC Form D ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07249489	Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada	Not phased (device or behavioral study)	Not yet recruiting	2026-10	2028-01 (estimated)
NCT07542184	Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Panama	Not phased (device or behavioral study)	Recruiting	Jul 30, 2026	2027-09 (estimated)